241 related articles for article (PubMed ID: 3265693)
41. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice.
Brusa P; Dosio F; Pacchioni D; Delprino L; Grosa G; Bussolati G; Cattel L
J Pharm Sci; 1994 Apr; 83(4):514-9. PubMed ID: 8046606
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer.
LoRusso PM; Lomen PL; Redman BG; Poplin E; Bander JJ; Valdivieso M
Am J Clin Oncol; 1995 Aug; 18(4):307-12. PubMed ID: 7625372
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
46. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
47. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
Robak T
Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
[No Abstract] [Full Text] [Related]
48. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
49. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
Cattel L; Delprino L; Brusa P; Dosio F; Comoglio PM; Prat M
Cancer Immunol Immunother; 1988; 27(3):233-40. PubMed ID: 3263208
[TBL] [Abstract][Full Text] [Related]
50. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
51. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
[TBL] [Abstract][Full Text] [Related]
53. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Brusa P; Dosio F; Pietribiasi F; Delprino L; Feraiorni P; Mariani M; Bussolati G; Cattel L
Cancer Immunol Immunother; 1992; 35(6):373-80. PubMed ID: 1394342
[TBL] [Abstract][Full Text] [Related]
54. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
55. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
56. Monoclonal antibody-ricin A chain conjugates (immunotoxins): potential therapeutic agents for human colon carcinoma.
Gallagher WJ; Burk MW
J Surg Res; 1986 Feb; 40(2):159-66. PubMed ID: 3945071
[TBL] [Abstract][Full Text] [Related]
57. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice.
Faguet GB; Agee JF
Leuk Lymphoma; 1997 May; 25(5-6):531-7. PubMed ID: 9250824
[TBL] [Abstract][Full Text] [Related]
58. Preparation and biological characterization of conjugates consisting of ricin and a tumor-specific non-internalizing MAb.
Cogliati T; Brusa P; Canevari S; Caldera M; Mezzanzanica D; Dosio F; Cattel L; Colnaghi MI
Anticancer Res; 1991; 11(1):417-21. PubMed ID: 2018380
[TBL] [Abstract][Full Text] [Related]
59. Application of anti-sialyl Lea monoclonal antibody, KM231, for immunotherapy of cancer.
Shitara K; Hanai N; Kusano A; Furuya A; Yoshida H; Wada K; Watanabe T; Sato S
Anticancer Res; 1991; 11(6):2003-13. PubMed ID: 1776833
[TBL] [Abstract][Full Text] [Related]
60. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
